Technique review |
Combining different ‘omics’ technologies to map and validate protein—protein interactions in humans
Senior vice-president of Systems Biology at MDS-Proteomics. Previously, he was a Research Officer at NRC-Canada doing proteomics development. He obtained a PhD from the University of Alberta and completed a postdoctoral position with Dr Ruedi Aebersold.
Daniel Figeys, MDS-Proteomics, 251 Attwell Drive, Toronto, Ontario M9W 7H4, Canada Tel: +1 416 644 5105 Fax: +1 416 644 5111 E-mail: dfigeys{at}mdsp.com
The mapping of protein–protein interactions is key to understanding biological processes. Many technologies have been reported to map interactions and these have been systematically applied in yeast. To date, the number of reported yeast protein interactions that have been truly validated by at least one other approach is low. The mapping of human protein interaction networks is even more complicated. Thus, it is unreasonable to try to map the human interactome; instead, interaction mapping in human cell lines should be focused along the lines of diseases or changes that can be associated with specific cells. In this paper, an approach for combining different ‘omics’ technologies to achieve efficient mapping and validation of protein interactions in human cell lines is presented.
Keywords: protein interactions, mass spectrometry, yeast two-hybrid, protein networks and systems biology
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Di Cara, K. Schmidt, B. A. Hemmings, and E. J. Oakeley PromoterPlot: a graphical display of promoter similarities by pattern recognition Nucleic Acids Res., July 1, 2005; 33(suppl_2): W423 - W426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Döhr, A. Klingenhoff, H. Maier, M. H. de Angelis, T. Werner, and R. Schneider Linking disease-associated genes to regulatory networks via promoter organization Nucleic Acids Res., February 8, 2005; 33(3): 864 - 872. [Abstract] [Full Text] [PDF]
|
|